Showing results (201-210 of 208) with videos related to
Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.Nature Medicine|January 16, 2026
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trialPriscilla K Brastianos, Katharine Dooley, Susan Geyer, et al.Clinical Genitourinary Cancer|May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology SubtypesDimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.Pageof 21